Open AccessREVIEW: REMDESIVIR AS A CANDIDATE FOR COVID-19 TREATMENT
Author(s) -
Iffah Anasia,
Zulharmita Zulharmita,
Ridho Asra
Publication year - 2021
Publication title -
international journal of pharmaceutical sciences and medicine
Language(s) - English
Resource type - Journals
ISSN - 2519-9889
DOI - 10.47760/ijpsm.2021.v06i08.012
Subject(s) - virology , virus , medicine , ebola virus , hendra virus , antiviral drug , measles virus , coronavirus , paramyxoviridae , covid-19 , measles , viral disease , disease , infectious disease (medical specialty) , vaccination
Remdesivir is the first drug that has been approved by the US Food and Drug Administration (FDA) for clinical use in hospitalized patients with COVID-19 disease. From several therapeutic options, Remdesivir is a direct-acting antiviral drug that has previously been tested against the Ebola virus, known to be effective and safe enough to inhibit the replication of SARS-CoV-2. Corona virus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that attacks the respiratory system in humans, this virus can cause mild disorders of the respiratory system, severe lung infections, and even death. Remdesivir is a broad-spectrum antiviral agent that has previously shown antiviral activity against filoviruses (Ebola and Marburg viruses), coronaviruses (SARS-CoV, MERS-CoV, SARS CoV-2), paramyxoviruses (type III influenza virus, Nipah virus, Hendra virus, measles, and mumps virus) and Pnemoviriidae (respiratory syncytial virus).